Related content

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite

The prognostic value of KRAS mutations in patients with colorectal cancer

By                  

Oncology Reports, Vol. 28, Iss. 5, 2012-01 ,pp. : 1579-1584

Spandidos Publications

Access to resources Recommend Favorite

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

By Nakanishi Ryota   Harada Jun   Tuul Munkhbold   Zhao Yan   Ando Koji   Saeki Hiroshi   Oki Eiji   Ohga Takefumi   Kitao Hiroyuki   Kakeji Yoshihiro   Maehara Yoshihiko  

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1042-1048

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancer

By                  

Oncology Letters, Vol. 10, Iss. 4, 2015-01 ,pp. : 2519-2526

Spandidos Publications

Access to resources Recommend Favorite

KRAS mutations and subtyping in colorectal cancer in Jordanian patients

By    

Oncology Letters, Vol. 4, Iss. 4, 2012-01 ,pp. : 705-710

Spandidos Publications

Access to resources Recommend Favorite